Last reviewed · How we verify
NCT05449717: PKDL
Incidence of Relapse and Post-Kala-Azar Dermal Leishmaniasis in South Sudan
trial in Leishmaniasis in 52 participants. Completed in 11 April 2025.
11 April 2025
Quick facts
| Lead sponsor | Epicentre |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 52 |
| Start date | 31 May 2022 |
| Primary completion | 11 April 2025 |
| Estimated completion | 11 April 2025 |
| Sites | 1 location across South Sudan |
Conditions studied
- Leishmaniasis — all drugs for Leishmaniasis →
- Leishmaniasis, Visceral — all drugs for Leishmaniasis, Visceral →
- Post-kala-azar Dermal Leishmaniasis — all drugs for Post-kala-azar Dermal Leishmaniasis →
Sponsor
Epicentre — full company profile →
Who can join
Eligibility, any sex, with Leishmaniasis or Leishmaniasis, Visceral. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study aims to describe the burden of Post-Kala-Azar Dermal Leishmaniasis and visceral leishmaniasis relapse in a cohort of patients discharged after successful treatment of primary visceral leishmaniasis.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05449717
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Leishmaniasis
Currently open trials in the same condition.
- NCT07358910 — Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective · recruiting
- NCT03784248 — Mediterranean Visceral Leishmaniasis With Leishmania Infantum · active not recruiting
- NCT00344188 — Diagnosis and Treatment of Leishmania Infections · recruiting
Other Epicentre trials
Trials by the same sponsor.
- NCT06382857 — Effectiveness of a Microbiome-directed Food to Promote Programmatic and Sustained Nutritional Recovery Among Children Wi · NA · recruiting
- NCT05551819 — Acceptability of a Microbiome-directed Food in Young Children With Acute Malnutrition · NA · completed
- NCT07506213 — Development, Feasibility and Acceptability of Recipes for Locally Available, Specially Formulated Foods for the Manageme · NA · completed
- NCT05453253 — Immune Response to a Delayed Second Dose of Oral Cholera Vaccine · Phase 4 · unknown
- NCT05175014 — Mass Campaigns With Fractional Dose Pneumococcal Vaccines in Sub-Saharan Africa (fPCV) · Phase 4 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05449717 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Epicentre
- Last refreshed: 24 April 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05449717.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing